XNW21015 / Evopoint - LARVOL DELTA

Discovery of XNW21015, a novel, potent HPK1 inhibitor with excellent immune modulatory activity (AACR 2023) - "In a humanized PDX (patient-derived xenograft) model, XNW21015 enhanced tumor-infiltrated lymphocytes (TIL). In summary, we have discovered a novel, highly potent and selective HPK1 inhibitor XNW21015 as promising small molecule I/O agent, as monotherapy or in combination with immune checkpoint inhibitors."

Oncology • LCP2